Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Prostatitis / CP-CPPS & Sexual Dysfunction

NIH Categories, Diagnostic Difficulty, and the Pain-Sex Connection

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (condition)

Reference only. Not medical advice.

This is something to take to a clinician. The Atlas can tell you what is known about prostatitis / cp-cpps & sexual dysfunction in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Prostatitis is classified by the NIH (1999, Krieger et al.) into four categories: I acute bacterial, II chronic bacterial, III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS, by far the most common, ~90-95% of cases, itself split into IIIA inflammatory and IIIB non-inflammatory), and IV asymptomatic inflammatory. CP/CPPS is a diagnosis of exclusion with no reliable test, and it is tightly linked to sexual dysfunction: studies report high rates of erectile dysfunction, premature or painful ejaculation, and post-ejaculatory pain. The pain-sex link runs both ways, pelvic floor dysfunction and central sensitization drive both symptoms.

The most common prostate diagnosis under 50 is the one no one can reliably diagnose, and it wrecks sex in ways rarely discussed.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Framework for pelvic-pain evaluation
  • Distinguishing bacterial from non-bacterial syndromes
  • Recognizing the sexual-dysfunction overlap

How it is supposed to work

Category I/II involve true uropathogen infection. CP/CPPS (III) likely is not a prostate infection at all in most men but a syndrome of pelvic-floor muscle dysfunction, neurogenic inflammation, and central pain sensitization, which is why antibiotics so often fail. The sexual link is mechanistic: pelvic-floor hypertonicity contributes to ejaculatory pain and premature/painful ejaculation; chronic pain and anxiety impair erectile function; and the shared autonomic dysregulation ties the two together. The UPOINT system (Shoskes) phenotypes patients (Urinary, Psychosocial, Organ-specific, Infection, Neurologic, Tenderness) to guide multimodal therapy rather than reflexive antibiotics.

What people get wrong

  • Often saidProstatitis is a prostate infection

    ActuallyOnly categories I and II are infections; the dominant category III (CP/CPPS) is usually not bacterial, which is why repeated antibiotic courses commonly fail.

  • Often saidIt is a minor nuisance

    ActuallyCP/CPPS can be chronic, disabling, and strongly associated with sexual dysfunction, depression, and reduced quality of life comparable to other chronic-pain conditions.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

What we do not know

  • Whether CP/CPPS is one disease or many overlapping syndromes.
  • Why pelvic-floor therapy helps some and not others.
  • The direction of causation between pelvic pain and sexual dysfunction.

At a glance

NIH classification
Krieger et al., 1999
CP/CPPS share
~90-95% of prostatitis cases
Hallmark
Chronic pelvic pain, often with ejaculatory pain
Sexual dysfunction
ED, premature/painful ejaculation common
Diagnostic test
None reliable; diagnosis of exclusion

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Prostatitis / CP-CPPS & Sexual Dysfunction. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Krieger et al., NIH prostatitis classification, JAMA1999

    Defined the four-category system and the CP/CPPS construct

  • Shoskes et al., UPOINT phenotyping2009

    Multimodal phenotype-directed therapy outperformed one-size-fits-all approaches

  • Ahn et al. and others, CP/CPPS and sexual dysfunction2010s

    Reported elevated rates of ED and ejaculatory dysfunction in CP/CPPS cohorts